ArticleBMJ open2025
Ursodeoxycholic acid for the prevention of severe radiation dermatitis: a single-arm phase I/II trial protocol in patients with breast cancer undergoing postoperative radiotherapy in China.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer poses a significant threat to public health, as demonstrated by its high incidence rate. While postoperative radiotherapy remains an important adjuvant treatment for patients with breast cancer undergoing breast-conserving surgery, radiation-induced dermatitis (RID) is a prevalent side effect, for which no standardised prevention method currently exists. Our previous preclinical research demonstrated that ursodeoxycholic acid (UDCA) significantly reduced radiation-induced skin damage in mice. Therefore, this phase I/II clinical study aims to further evaluate the safety and efficacy of UDCA in preventing RID during adjuvant radiotherapy in patients with breast cancer after breast-conserving surgery. METHODS AND ANALYSIS: This single-centre phase I/II clinical study, with a single-arm cohort design in phase II, will include female patients who have undergone adjuvant radiotherapy after breast-conserving surgery for breast cancer. The sample size for the study is 40. Eligible patients will receive adjuvant radiotherapy at a prescribed dose of 50 Gy/25 F to the entire breast and lymphatic drainage area, where indicated, and 66 Gy/33 F to the tumour bed. After each irradiation, a 250 mg dose of UDCA will be topically administered to the irradiated area. Radiological dermatitis and skin temperature were assessed once a week after the initiation of radiotherapy, and haematological toxicity, radiation lung injury and quality of life were monitored and analysed on a regular basis until the second week after the conclusion of radiotherapy. The primary objectives of phase I and II studies are the safety profile and incidence of grade II or higher RID in patients, respectively. ETHICS AND DISSEMINATION: This study was approved by the ethics committee of Mianyang Central Hospital, China (No: S20230211-02) and is registered in the Chinese Clinical Trial Register (registration number: ChiCTR2400085925). Results will be published in peer-reviewed journals. TRIAL REGISTRATION NUMBER: ChiCTR2400085925.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.